• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Innopran XL (propranolol hydrochloride) capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2010

Summary View

 

WARNINGS

Hypersensitivity and Skin Reactions:
  • Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, have been associated with the administration of propranolol hydrochloride. Cutaneous reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis,exfoliative dermatitis, erythema multiforme, and urticaria, have been reported with use of propranolol hydrochloride.

Major Surgery

  • Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery.

PRECAUTIONS

Myopathy
  • Caution should be exercised when administering propranolol Hydrochloride to patients with underlying skeletal muscle disease. Isolated cases of exacerbation of myopathy and myotonia have been reported.
Drug Interactions
  • Plasma propranolol hydrochloride levels may increase with acute alcohol consumption and decrease upon chronic alcohol use.
Pregnancy
  • small placentas, and congenital abnormalities have been reported

ADVERSE REACTIONS

Allergic
  • Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions; pharyngitis and agranulocytosis; erythematous rash, fever combined with aching and sore throat, laryngospasm, and respiratory distress.
Skin
  • Stevens-Johnson syndrome; toxic epidermal necrolysis; exfoliative dermatitis; Erythemamultiforme; urticaria.
Musculoskeletal
  • Myopathy, myotonia.